U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Myelodysplastic Syndrome Post Cytotoxic Therapy

MedGen UID:
224863
•Concept ID:
C1292780
•
Neoplastic Process
Synonyms: MDS Post Cytotoxic Therapy; Therapy Related Myelodysplastic Syndrome; Therapy-Related MDS; Therapy-related myelodysplastic syndrome; Therapy-Related Myelodysplastic Syndrome
SNOMED CT: Therapy-related myelodysplastic syndrome (702476004)

Definition

A myelodysplastic syndrome resulting from chemotherapy or radiation therapy for cancer. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMyelodysplastic Syndrome Post Cytotoxic Therapy

Professional guidelines

PubMed

Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Auger N, Douet-Guilbert N, Quessada J, Theisen O, Lafage-Pochitaloff M, Troadec MB
Curr Res Transl Med 2023 Oct-Dec;71(4):103409. Epub 2023 Sep 17 doi: 10.1016/j.retram.2023.103409. PMID: 38091642
Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation.
Yu XX, Cao XH, Yan H, Luo XY, Zhao XS, Sun YQ, Wang Y, Xu LP, Zhang XH, Chang YJ, Huang XJ, Zhao XY
Clin Immunol 2019 Aug;205:49-56. Epub 2019 May 18 doi: 10.1016/j.clim.2019.05.010. PMID: 31112757
The role of azacitidine in the treatment of myelodysplastic syndromes.
Abdulhaq H, Rossetti JM
Expert Opin Investig Drugs 2007 Dec;16(12):1967-75. doi: 10.1517/13543784.16.12.1967. PMID: 18042004

Recent clinical studies

Etiology

Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Auger N, Douet-Guilbert N, Quessada J, Theisen O, Lafage-Pochitaloff M, Troadec MB
Curr Res Transl Med 2023 Oct-Dec;71(4):103409. Epub 2023 Sep 17 doi: 10.1016/j.retram.2023.103409. PMID: 38091642
Therapy-related myelodysplastic syndromes in the genomics era.
Renneville A, Bernard E, Micol JB
Bull Cancer 2023 Nov;110(11):1129-1140. Epub 2023 Jun 28 doi: 10.1016/j.bulcan.2023.02.022. PMID: 37391357
Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation.
Yu XX, Cao XH, Yan H, Luo XY, Zhao XS, Sun YQ, Wang Y, Xu LP, Zhang XH, Chang YJ, Huang XJ, Zhao XY
Clin Immunol 2019 Aug;205:49-56. Epub 2019 May 18 doi: 10.1016/j.clim.2019.05.010. PMID: 31112757
The role of azacitidine in the treatment of myelodysplastic syndromes.
Abdulhaq H, Rossetti JM
Expert Opin Investig Drugs 2007 Dec;16(12):1967-75. doi: 10.1517/13543784.16.12.1967. PMID: 18042004
The incidence of secondary leukemias.
Leone G, Mele L, Pulsoni A, Equitani F, Pagano L
Haematologica 1999 Oct;84(10):937-45. PMID: 10509043

Diagnosis

Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Auger N, Douet-Guilbert N, Quessada J, Theisen O, Lafage-Pochitaloff M, Troadec MB
Curr Res Transl Med 2023 Oct-Dec;71(4):103409. Epub 2023 Sep 17 doi: 10.1016/j.retram.2023.103409. PMID: 38091642
An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!
Haddad F, Daver N
Adv Exp Med Biol 2021;1342:273-295. doi: 10.1007/978-3-030-79308-1_9. PMID: 34972969
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.
Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, Garcia-Manero G, Wang SA, Hasserjian RP
J Clin Oncol 2012 Jul 1;30(19):2340-7. Epub 2012 May 14 doi: 10.1200/JCO.2011.38.7340. PMID: 22585703Free PMC Article
Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies.
Ok CY, Medeiros LJ, Hu Y, Bueso-Ramos CE, Wang SA
Leuk Res 2011 Dec;35(12):1605-10. Epub 2011 May 18 doi: 10.1016/j.leukres.2011.04.021. PMID: 21596435
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Ritchie D, Came N, Seymour JF
Leukemia 2010 Dec;24(12):2056-62. Epub 2010 Oct 21 doi: 10.1038/leu.2010.218. PMID: 20962860

Therapy

Therapy-related myelodysplastic syndromes in the genomics era.
Renneville A, Bernard E, Micol JB
Bull Cancer 2023 Nov;110(11):1129-1140. Epub 2023 Jun 28 doi: 10.1016/j.bulcan.2023.02.022. PMID: 37391357
LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders.
Hong J, Ni J, Ruan M, Yang M, Dong Q, Li Q
Int J Hematol 2020 Jun;111(6):851-857. Epub 2020 Mar 11 doi: 10.1007/s12185-020-02844-7. PMID: 32162095
Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation.
Yu XX, Cao XH, Yan H, Luo XY, Zhao XS, Sun YQ, Wang Y, Xu LP, Zhang XH, Chang YJ, Huang XJ, Zhao XY
Clin Immunol 2019 Aug;205:49-56. Epub 2019 May 18 doi: 10.1016/j.clim.2019.05.010. PMID: 31112757
The role of iron in patients after bone marrow transplantation.
de Witte T
Blood Rev 2008 Dec;22 Suppl 2:S22-8. doi: 10.1016/S0268-960X(08)70005-5. PMID: 19059053
Farnesyltransferase inhibitors.
Sebti SM, Adjei AA
Semin Oncol 2004 Feb;31(1 Suppl 1):28-39. doi: 10.1053/j.seminoncol.2003.12.012. PMID: 14981578

Prognosis

Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Auger N, Douet-Guilbert N, Quessada J, Theisen O, Lafage-Pochitaloff M, Troadec MB
Curr Res Transl Med 2023 Oct-Dec;71(4):103409. Epub 2023 Sep 17 doi: 10.1016/j.retram.2023.103409. PMID: 38091642
Therapy-related myelodysplastic syndromes in the genomics era.
Renneville A, Bernard E, Micol JB
Bull Cancer 2023 Nov;110(11):1129-1140. Epub 2023 Jun 28 doi: 10.1016/j.bulcan.2023.02.022. PMID: 37391357
Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
Claiborne J, Bandyopathyay D, Roberts C, Hawks K, Aziz M, Simmons G, Wiedl C, Chung H, Clark W, McCarty J, Toor A
Leuk Lymphoma 2019 Nov;60(11):2733-2743. Epub 2019 May 3 doi: 10.1080/10428194.2019.1605066. PMID: 31046498
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial.
Wermke M, Eckoldt J, Götze KS, Klein SA, Bug G, de Wreede LC, Kramer M, Stölzel F, von Bonin M, Schetelig J, Laniado M, Plodeck V, Hofmann WK, Ehninger G, Bornhäuser M, Wolf D, Theurl I, Platzbecker U
Lancet Haematol 2018 May;5(5):e201-e210. Epub 2018 Apr 5 doi: 10.1016/S2352-3026(18)30036-X. PMID: 29628397
The incidence of secondary leukemias.
Leone G, Mele L, Pulsoni A, Equitani F, Pagano L
Haematologica 1999 Oct;84(10):937-45. PMID: 10509043

Clinical prediction guides

Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Auger N, Douet-Guilbert N, Quessada J, Theisen O, Lafage-Pochitaloff M, Troadec MB
Curr Res Transl Med 2023 Oct-Dec;71(4):103409. Epub 2023 Sep 17 doi: 10.1016/j.retram.2023.103409. PMID: 38091642
Therapy-related myelodysplastic syndromes in the genomics era.
Renneville A, Bernard E, Micol JB
Bull Cancer 2023 Nov;110(11):1129-1140. Epub 2023 Jun 28 doi: 10.1016/j.bulcan.2023.02.022. PMID: 37391357
An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!
Haddad F, Daver N
Adv Exp Med Biol 2021;1342:273-295. doi: 10.1007/978-3-030-79308-1_9. PMID: 34972969
Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.
Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA, Dean R, Bishop MR, Gress RE, Hakim FT
Biol Blood Marrow Transplant 2008 Mar;14(3):290-300. doi: 10.1016/j.bbmt.2007.12.490. PMID: 18275895
Post-transfusion purpura: a heterogeneous syndrome.
Zeigler Z, Murphy S, Gardner FH
Blood 1975 Apr;45(4):529-36. PMID: 1115841

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...